Eckuity Bets on Lab AI with Fund II's First Investment in Automata

NEW YORK, NY – June 25, 2026 – In a move that signals strong confidence in the commercial future of artificial intelligence within life sciences, healthcare growth equity firm Eckuity Capital has announced the first close of its second fund, Eckuity Capital Fund II. The firm wasted no time in deploying capital, leading a Series C investment in Automata Technologies, a trailblazer in AI-driven laboratory automation. The investment, made alongside global science and technology conglomerate Danaher, marks a significant milestone for Eckuity and serves as a powerful validation of Automata's mission to revolutionize scientific work.

This inaugural investment sets a clear tone for Fund II, reinforcing Eckuity's core thesis: identifying and scaling commercial-stage companies poised to translate cutting-edge innovation into tangible market success. The strategic alignment of a specialized growth equity firm and a corporate titan behind a high-growth tech company provides a compelling case study in accelerating the journey from prototype to profit.

Eckuity’s Calculated Expansion

The launch of Fund II represents a natural evolution for Eckuity Capital, which was founded in 2021 and quickly established its presence. The firm’s first fund, a $155 million vehicle, was fully deployed across a portfolio of 14 companies, proving out a strategy that combines capital infusion with deep, hands-on commercialization support. Eckuity's model moves beyond passive investment, leveraging its operational expertise through its affiliate, Nettwork Holdings, to build market access and guide companies through the complex regulatory and commercial landscapes of healthcare.

Underscoring this strategic expansion is the recent strengthening of Eckuity’s leadership team with the addition of Paul Enever and Alejandro Sanchez as Partners. Their pedigrees signal a doubling down on the firm’s value-add approach. Enever, a former McKinsey partner with 25 years in medical technology, brings a wealth of experience scaling MedTech ventures, with notable exits including Cardiva Medical's acquisition by Haemonetics. Sanchez, also a McKinsey alumnus and co-founder of Hermes Growth Partners, has a proven track record in growth equity and strategic advisory, including the successful exit of Biotheranostics to Hologic. Their combined expertise in navigating the path to commercial viability will be instrumental in executing Fund II's strategy.

“Healthcare will change more in the next decade than it has in a generation, and the firms that matter will be the ones turning artificial intelligence into tools clinicians and scientists actually use,” said Youssef Sebban, Founder and Managing Partner of Eckuity Capital, in a recent statement. “Opening Fund II with our first investment in Automata, alongside Danaher, is the standard we intend to set.”

The Strategic Bet on Lab Automation

At the heart of this announcement is Automata Technologies. The company is tackling a long-standing bottleneck in the life sciences industry: the manual, slow, and often error-prone nature of laboratory work. By integrating robotics with sophisticated artificial intelligence, Automata aims to create the 'lab of the future,' where repetitive tasks are automated, data is captured seamlessly, and scientists are freed up to focus on higher-value work like experimental design and analysis. This automation is critical for increasing throughput, improving reproducibility, and ultimately accelerating the pace of scientific discovery and development.

The investment from Eckuity and Danaher is more than just capital; it's a strategic endorsement of Automata's approach. For a company moving from a novel technology to a scalable commercial product, securing partners who understand both the technical intricacies and the market dynamics is paramount.

“Automating the lab is one of the highest-leverage problems in science, and solving it takes partners who understand both the technology and the path to commercial scale,” noted Mostafa ElSayed, CEO of Automata Technologies. “Eckuity led our Series C because they understood exactly what we are building.” This sentiment highlights the importance of investor-founder alignment, a cornerstone of successful commercialization.

The Power of Synergistic Backing

The composition of Automata's Series C investors is particularly noteworthy. The partnership between Eckuity Capital, a nimble growth equity specialist, and Danaher, a strategic industry behemoth, creates a powerful synergy. This collaborative backing provides Automata with a unique combination of resources that few growth-stage companies can access.

From Eckuity, Automata gains a hands-on partner dedicated to building commercial infrastructure and navigating go-to-market challenges. From Danaher, it gains unparalleled market validation, potential access to a global distribution network, and deep insights from a company that lives and breathes the life sciences and diagnostics markets. Danaher’s participation is consistent with its broader strategy of embracing advanced technologies and AI to enhance its portfolio. The conglomerate's recent focus on AI-enabled features in its diagnostics and MedTech segments, such as within its acquired Masimo business, demonstrates a clear strategic interest in the very space Automata aims to dominate. This dual-track support system significantly de-risks Automata's commercial journey and provides a formidable competitive advantage.

From Fund I Success to Fund II Ambition

Eckuity Capital’s confidence in its strategy is built on a solid foundation. The firm's first fund established a clear track record of identifying promising commercial-stage companies across HealthTech, MedTech, and biotech services. The portfolio includes a diverse range of innovators, from therapeutic device company Samsara Vision to diagnostic equipment maker Kardium and digital surgery platform Caresyntax. The successful exits of Caresyntax and Entalpi from this first fund have already provided tangible proof of the model's efficacy.

The strategy for Fund II, as exemplified by the Automata investment, is a direct continuation of this successful approach. By targeting companies with established products and clear revenue traction, Eckuity focuses its efforts where it can have the most impact: scaling the business. The decision to lead Automata's Series C, bringing a powerhouse like Danaher to the table, demonstrates not just continuity but a heightened level of ambition and execution for its second fund. As Eckuity continues to build out its Fund II portfolio through the year, the market will be watching closely to see which other innovators are chosen to help redefine the commercial landscape of modern healthcare.